181 related articles for article (PubMed ID: 31014129)
21. Effect of storage temperature on the stability of spray dried bacteriophage powders.
Leung SSY; Parumasivam T; Nguyen A; Gengenbach T; Carter EA; Carrigy NB; Wang H; Vehring R; Finlay WH; Morales S; Britton WJ; Kutter E; Chan HK
Eur J Pharm Biopharm; 2018 Jun; 127():213-222. PubMed ID: 29486303
[TBL] [Abstract][Full Text] [Related]
22. Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: Spray drying versus spray freeze drying preparation.
Yu H; Teo J; Chew JW; Hadinoto K
Int J Pharm; 2016 Feb; 499(1-2):38-46. PubMed ID: 26757148
[TBL] [Abstract][Full Text] [Related]
23. Novel dry powder inhalation system based on dispersion of lyophilisates.
Claus S; Schoenbrodt T; Weiler C; Friess W
Eur J Pharm Sci; 2011 May; 43(1-2):32-40. PubMed ID: 21440061
[TBL] [Abstract][Full Text] [Related]
24. Budesonide dry powder for inhalation: effects of leucine and mannitol on the efficiency of delivery.
Rattanupatam T; Srichana T
Drug Deliv; 2014 Sep; 21(6):397-405. PubMed ID: 24401124
[TBL] [Abstract][Full Text] [Related]
25. Aerosolization properties, surface composition and physical state of spray-dried protein powders.
Bosquillon C; Rouxhet PG; Ahimou F; Simon D; Culot C; Préat V; Vanbever R
J Control Release; 2004 Oct; 99(3):357-67. PubMed ID: 15451594
[TBL] [Abstract][Full Text] [Related]
26. A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics.
Chan JG; Chan HK; Prestidge CA; Denman JA; Young PM; Traini D
Eur J Pharm Biopharm; 2013 Feb; 83(2):285-92. PubMed ID: 22982733
[TBL] [Abstract][Full Text] [Related]
27. Understanding the impact of mannitol on physical stability and aerosolization of spray-dried protein powders for inhalation.
Arte KS; Tower CW; Mutukuri TT; Chen Y; Patel SM; Munson EJ; Tony Zhou Q
Int J Pharm; 2024 Jan; 650():123698. PubMed ID: 38081559
[TBL] [Abstract][Full Text] [Related]
28. Physical characteristics and aerosolization performance of insulin dry powders for inhalation prepared by a spray drying method.
You Y; Zhao M; Liu G; Tang X
J Pharm Pharmacol; 2007 Jul; 59(7):927-34. PubMed ID: 17637186
[TBL] [Abstract][Full Text] [Related]
29. Low powder mass filling of dry powder inhalation formulations.
Eskandar F; Lejeune M; Edge S
Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
[TBL] [Abstract][Full Text] [Related]
30. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients.
Minne A; Boireau H; Horta MJ; Vanbever R
Eur J Pharm Biopharm; 2008 Nov; 70(3):839-44. PubMed ID: 18620052
[TBL] [Abstract][Full Text] [Related]
31. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance.
Bosquillon C; Lombry C; Préat V; Vanbever R
J Control Release; 2001 Feb; 70(3):329-39. PubMed ID: 11182203
[TBL] [Abstract][Full Text] [Related]
32. Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability.
Arora S; Haghi M; Young PM; Kappl M; Traini D; Jain S
Expert Opin Drug Deliv; 2016; 13(2):183-93. PubMed ID: 26609733
[TBL] [Abstract][Full Text] [Related]
33. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
34. Aerosolization behavior of carrier-free L-leucine coated salbutamol sulphate powders.
Raula J; Lähde A; Kauppinen EI
Int J Pharm; 2009 Jan; 365(1-2):18-25. PubMed ID: 18789380
[TBL] [Abstract][Full Text] [Related]
35. Development of controlled-release cisplatin dry powders for inhalation against lung cancers.
Levet V; Rosière R; Merlos R; Fusaro L; Berger G; Amighi K; Wauthoz N
Int J Pharm; 2016 Dec; 515(1-2):209-220. PubMed ID: 27737810
[TBL] [Abstract][Full Text] [Related]
36. Inhalable spray-dried formulation of D-LAK antimicrobial peptides targeting tuberculosis.
Kwok PC; Grabarek A; Chow MY; Lan Y; Li JC; Casettari L; Mason AJ; Lam JK
Int J Pharm; 2015 Aug; 491(1-2):367-74. PubMed ID: 26151107
[TBL] [Abstract][Full Text] [Related]
37. Development of inhalable dry powder formulation of basic fibroblast growth factor.
Ibrahim BM; Jun SW; Lee MY; Kang SH; Yeo Y
Int J Pharm; 2010 Jan; 385(1-2):66-72. PubMed ID: 19853028
[TBL] [Abstract][Full Text] [Related]
38. Optimization and characterization of dry powder of fanhuncaoin for inhalation based on selection of excipients.
Yang XB; Wang XB; Pan WS; Xi RG; Wang YN; Liu D; Shi Y; Jiang S
Chem Pharm Bull (Tokyo); 2011; 59(8):929-37. PubMed ID: 21804235
[TBL] [Abstract][Full Text] [Related]
39. Aerosolizable gold nano-in-micro dry powder formulations for theragnosis and lung delivery.
Silva AS; Sousa AM; Cabral RP; Silva MC; Costa C; Miguel SP; Bonifácio VDB; Casimiro T; Correia IJ; Aguiar-Ricardo A
Int J Pharm; 2017 Mar; 519(1-2):240-249. PubMed ID: 28111281
[TBL] [Abstract][Full Text] [Related]
40. Effects of different mesh nebulizer sources on the dispersion of powder formulations produced with a new small-particle spray dryer.
Aladwani G; Momin MAM; Spence B; Farkas DR; Bonasera S; Hassan A; Hindle M; Longest W
Int J Pharm; 2023 Jul; 642():123138. PubMed ID: 37307962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
